Skip to main content

LON:AMYT - Amryt Pharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 166
▼ -0.5 (-0.30%)
1 month | 3 months | 12 months
Get New Amryt Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMYT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMYT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Amryt Pharma in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 166.

N/A

The current consensus among 0 polled investment analysts is to n/a stock in Amryt Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/5/2021Shore CapitalReiterated RatingHouse Stock
i
3/3/2021Shore CapitalReiterated RatingHouse Stock
i
12/17/2020Shore CapitalReiterated RatingHouse Stock
i
10/29/2020Shore CapitalReiterated RatingHouse Stock
i
5/18/2020Berenberg BankReiterated RatingHouse Stock
i
5/11/2020Shore CapitalReiterated RatingHold
i
10/1/2019Shore CapitalReiterated RatingHouse Stock
i
8/29/2019Shore CapitalReiterated RatingHouse Stock
i
1/31/2018Beaufort SecuritiesReiterated RatingSpeculative Buy
i
1/9/2018Beaufort SecuritiesReiterated RatingSpeculative Buy
i
12/21/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 65
i
11/14/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 65
i
9/24/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 65
i
9/22/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 65
i
9/21/2017Shore CapitalLower Price Targethouse stockGBX 86 ➝ GBX 70
i
8/31/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 62
i
7/26/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 62
i
5/29/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 62
i
5/23/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 62
i
4/25/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
i
4/24/2017Stifel NicolausReiterated RatingBuyGBX 60
i
4/4/2017Stifel NicolausReiterated RatingBuyGBX 60
i
4/3/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
i
3/28/2017Shore CapitalReiterated Ratinghouse stock
i
3/28/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
i
3/7/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
i
2/7/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
i
2/6/2017Stifel NicolausReiterated RatingBuyGBX 49
i
12/5/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
9/20/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
9/14/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
8/10/2016Shore CapitalReiterated Ratinghouse stock
i
6/27/2016Shore CapitalReiterated Ratinghouse stock
i
6/10/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
6/9/2016Shore CapitalReiterated Ratinghouse stock
i
(Data available from 5/16/2016 forward)
Amryt Pharma logo
Amryt Pharma plc, a biopharmaceutical company, develops and commercializes therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is based in London, the United Kingdom.
Read More

Today's Range

Now: GBX 166
163.10
168

50 Day Range

MA: GBX 197.23
161.50
209

52 Week Range

Now: GBX 166
2
250

Volume

41,147 shs

Average Volume

114,712 shs

Market Capitalization

£297.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Amryt Pharma?

The following Wall Street sell-side analysts have issued reports on Amryt Pharma in the last twelve months: Berenberg Bank, and Shore Capital.
View the latest analyst ratings for AMYT.

What is the current price target for Amryt Pharma?

0 Wall Street analysts have set twelve-month price targets for Amryt Pharma in the last year. has the lowest price target set, forecasting a price of £100,000 for Amryt Pharma in the next year.
View the latest price targets for AMYT.

What is the current consensus analyst rating for Amryt Pharma?

Amryt Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AMYT.

What other companies compete with Amryt Pharma?

How do I contact Amryt Pharma's investor relations team?

Amryt Pharma's physical mailing address is Ivybridge House, 1 Adam Street, LONDON, WC2N 6LE, United Kingdom. The company's listed phone number is +44-20-34155730. The official website for Amryt Pharma is www.amrytpharma.com.